Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
01:14pm, Wednesday, 28'th Feb 2024
TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Wednesday, 28'th Feb 2024
TG Therapeutics (TGTX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.39 per share a year ago.
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
07:00am, Wednesday, 28'th Feb 2024
Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET NEW YORK,
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
07:30am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO)
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
07:00am, Monday, 26'th Feb 2024
Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
07:30am, Friday, 23'rd Feb 2024
Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
11:06am, Tuesday, 20'th Feb 2024
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
10:00am, Wednesday, 10'th Jan 2024
TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance
TG Therapeutics stock popped 11% on Wednesday: here's why
09:28am, Wednesday, 10'th Jan 2024
Shares of TG Therapeutics Inc (NASDAQ: TGTX) opened 11% up on Wednesday after the biopharmaceutical firm said it sees a meaningful increase in its revenue from Briumvi this year. TG Therapeutics issue
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
07:36am, Wednesday, 10'th Jan 2024
TG Therapeutics Inc.'s stock TGTX, -1.36% rallied 11% early Wednesday, after the biotech said it's entered an agreement with microcap Precision BioSciencies Inc. DTIL, +10.10% to acquire a worldwide l
TGTX stock price Has the TG Therapeutics train left the station?
09:55am, Wednesday, 06'th Dec 2023
TG Therapeutics (NASDAQ: TGTX) stock price continued its recovery after the company published strong financial results. The shares jumped to the psychologically important level of $15, its highest poi
TG Therapeutics: Trying To Fill The Gap Back To $20
04:36am, Tuesday, 28'th Nov 2023
TG Therapeutics' Q3'23 net sales of Briumvi of $25.1M seemed to impress the market. Q3'23 sales of Briumvi were aided by J-code availability and increases in payor coverage. Q4'23 sales are hard to pr
Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect?
11:17am, Monday, 06'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, t
TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript
01:51am, Sunday, 05'th Nov 2023
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - C
Why TG Therapeutics Stock Is Crushing It Today
12:18pm, Wednesday, 01'st Nov 2023
The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisingly good results.
